- In May 2024, Zoetis Inc., a leading global animal health company, launched a next-generation oral antihistamine product designed specifically for treating chronic atopic dermatitis in dogs. The new formulation offers improved palatability and extended-release properties, aiming to enhance compliance among pet owners and therapeutic outcomes in companion animals
- In April 2024, Elanco Animal Health Incorporated announced a strategic partnership with veterinary hospitals across the U.S. to expand the availability of its injectable H1-receptor antagonist products for acute allergic reactions in pets. This initiative supports rapid in-clinic treatment and positions Elanco as a front-runner in the emergency veterinary care segment
- In February 2024, Vetoquinol S.A. unveiled its latest veterinary topical antihistamine solution targeting dermatitis and allergic flare-ups in both dogs and cats. The product utilizes a combination of antihistamines and soothing agents for localized relief and is expected to drive sales in retail and online pharmacies across Europe
- In December 2023, Boehringer Ingelheim Animal Health introduced a new line of combination therapy products that include antihistamines and corticosteroids for use in companion animals. These combination therapies are designed to address more complex allergic conditions such as chronic pruritus and have received strong early demand in North America and Asia-Pacific markets
- In October 2023, Virbac expanded its antihistamine product range in Latin America by launching loratadine-based chewable tablets for dogs with seasonal allergies. This move aligns with the growing demand for easy-to-administer, pet-friendly formulations in developing veterinary pharmaceutical markets
